Effect of serum HE4 and CP2 contents on expression of clinical pathological molecules and proliferation molecules in tumor tissue of patients with endometrial carcinoma

• Main Authors: Zhe Zhou, Xin Jiang, Ji-Cheng Song, Hong-Yan Jia
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2016-07-01
• Series: Journal of Hainan Medical University
• Subjects: Endometrial carcinoma; HE4; CP2; Proto-oncogene
• Online Access: http://www.hnykdxxb.com/PDF/201613/23.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To study the effect of serum HE4 and CP2 contents on the expression of clinical pathological molecules and proliferation molecules in tumor tissue of patients with endometrial carcinoma. Methods: A total of 40 cases of patients who were diagnosed with endometrial carcinoma in our hospital from May 2013 to March 2016 as well as 40 cases of healthy volunteers who received physical examination in our hospital during the same period were selected for study, serum samples were collected to detect HE4, c-myc, ZEB1, CP2, sTn, CA125, CA199 contents, and endometrial carcinoma tissue as well as para-carcinoma tissue were collected to detect P53, E-cad, EpCAM, C-erbB-2, Ki-67 and MACC1 contents. Results: Serum CP2 and HE4 contents of patients with endometrial carcinoma were significantly higher than those of healthy volunteers, and serum CP2 and HE4 contents of endometrial carcinoma patients with FIGO III-IV stage, low differentiation, muscular layer involvement more than 1/2 and cervical involvement were significantly higher than those of endometrial carcinoma patients with FIGO I-II stage, middle and high differentiation, muscular layer involvement less than 1/2 and without cervical involvement; serum CA125, CA199, c-myc, sTn and ZEB1 contents of patients with endometrial carcinoma were significantly higher than those of healthy volunteers and positively correlated with serum HE4 and CP2; P53 and E-cad contents in endometrial carcinoma tissue were significantly lower than those in para-carcinoma tissue and negatively correlated with serum HE4 and CP2, and EpCAM, C-erbB-2, Ki-67 and MACC1 contents were significantly higher than those in para-carcinoma tissue and positively correlated with serum HE4 and CP2. Conclusions: Serum HE4 and CP2 contents abnormally increase in patients with endometrial carcinoma, and serum HE4 and CP2 can be used to assess the clinical pathology of tumor as well as the degree of tumor tissue proliferation.